Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
well...that sounds awesome. this is the same company that promoted SAFS with a 1 trillion share structure at .0001. : /
Hey, 'ccharon86', dude! Dump NEXS at a paltry $1.40!! L.O.L.! Are you kidding?! I MAY 'dump' NEXS when it hits $1,400 up on the Big League NYSE!! Heck, if a garden-variety Mexican taco joint like "Chipolte" can skyrocket to over $700, then NEXS can hit $7,000!! And, you don't have to worry about contracting E. coli in the process!! Hey, dude, the boys over at "TradersChoice" have waited for YEARS for this monster NEXS penny pick! It is the BEST pick on the entire Planet, right now, and for years to come! Take it from the self-proclaimed "Prophet of Profits" --- namely me, Up/DownTrader --- NEXS is primed to EXPLODE!! Tighten your seatbelts, "$1.40" dude!!!!
1.40 area is the dump. half way into the promo there will be two big shake outs. just sit tight and enjoy this one. we won't get another trade from them until next year.
TARGET PRICE FOR 4Q 2016 AT 4.50. dont know how much of that i believe from nexus but guess we ll just wait and see.
News: Nexus BioPharma Announces Agreement with TransChem for Kinase
OCTOBER 7, 2016
Inhibition TechnologyFont size: A | A | A
Nexus BioPharma, Inc. (OTC-BB NEXS), a company specializing in the development of a weight loss drug therapy, announced today that it has reached an agreement with TransChem, Inc. to license TransChem's proprietary transition state chemistry technology for kinase inhibition.
Kinases are enzymes that regulate essential cellular processes. The U.S. Food and Drug Administration's milestone approval in 2001 of the first kinase inhibitor, imatinib, was followed by a steady approval of kinase inhibitors over the next 10 years. To date, The FDA has approved 28 small-molecule kinase inhibitors, half of which were approved in the last 3 years.
Warren C. Lau, President and CEO of Nexus BioPharma, Inc. stated, "We are pleased to acquire this groundbreaking technology that will not only enable us to develop our second generation weight loss preparation but will make Nexus a major player in the development of safer and more effective kinase inhibitors for a wide variety of conditions in this rapidly growing sector of the pharmaceutical market."
The overall kinase inhibitor market is estimated by BCC Research to reach $40.2 billion in 2016.
About Transition State Chemistry
The transition state is the moment at which the chemical bond decides if it will break or reform. It is the exceedingly short time during which there is an equal probability of nudging atoms to form new products or returning them to their original configuration. By replicating a shape that exists for the femtosecond lifetime of the transition state, and creating a chemical copy of that shape, it becomes possible to completely halt the action of the enzyme and freeze an enzymatic reaction. These synthetic mimics are called "transition-state analogs" and are as powerful as any enzyme inhibitors ever created. Because they are specific and required in extremely small doses, transition-state analogs provide an approach that could revolutionize how drugs are developed.
About Nexus BioPharma www.nexusbiopharma.com
Up/downtrader, getting plenty of rain and everywhere flooding I stay away from water and Ohio is a little too cold... Seem like nexs is a good one
Hey, NONON2 & Sylvia! I thought you guys were talking about NEXS --- not that Hurricane! Sorry 'bout that! So, don't worry about NEXS --- it will do just fine --- but maybe it's time for Sylvia to take a flight to Cleveland, Ohio, for a minute! Little better weather over there. Sylvia, don't take your boat out for at least a few days!
Up/DownTrader
Hey, NONON2, road-dog-homie! Don't fret, dude! Imminent NEXS EXPLOSION --- maintain a safe distance! If yesterday's sissy sell-off couldn't trash this play, then NOTHING will!! When NEXS takes-off monster time, make sure your BANK accounts are covered to the maximum extent of the FDIC!! You may need to open multiple accounts to hold the sudden tsunami of CASH!
Up/Down Trader,
The Prophet of Profits!!
"As it is written, so it shall be done!!!"
Thanks so much I am its a mad house around here
Evacuate and be safe! This looks really bad.
I saw u over on this board I am preparing for hurricane matthew I am in his path
"Re-enter" is NOT going to be $0.65, dude! Before you know it, NEXS will "re-enter" the NASDAQ at circa $6.50; and then "re-enter" the NYSE at circa $650.00! And, of course, "re-enter" my bank account, BIG TIME!!! Get ready to RUMBLE!!!
*** As it is written, so it shall be done! ***
Sincerely yours,
UP/DownTrader,
The Prophet of Profits!
Hey, Proartic dude! Yes, big sell-off today, but who cares?! I don't. Today, I configured a Fidelity (my broker) ALERT at $1.00 for my NEXS gamble. So, until I get a Fidelity email behind a NEXS $1.00+ move, well, I'm just gonna kick-back and watch some NFL. Fret not, dude! NEXS will be on the NASDAQ in a minute. No big deal. Me? I'll think about selling NEXS when it hits $100.00 per share. Like Donald Trump told his daughter as a kid: "When you grow up, you are likely to be thinking anyway --- so, think BIG!"
Sincerely yours,
Up/DownTrader
Re enter is .65
This is great.... they left you out man. You can thank posilock
Jeez who keeps dumping off their shares. We so need to make a timed syncronized board dump and buy back so we can profit even more ??
It came from tradeoftheyear.com
It came in an email.
Hello, 'Nonon2' dude!! THANKS for that (screen-shot) link! But, the good news thereupon behind NEXS is cut-off on the bottom of that PNG image. Is there any way, at your leisure, dude, to give us a LINK to that entire article? Anyway, THANKS! (Little jitters today behind the NEXS price, but it's coming back, BIGTIME!!)
Perfect move, 'Kool' dude! You likely tossed circa $10K at it, then grabbed you nice $3K chunk! And all while kicking-back in your LazyBoy lounge chair --- "Model 10,000" (with Remote Control, Bluetooth, & GPS Satellite Link).
Bottom line, NOBODY should ever toss more than $2K-$10K greenbacks at ANY penny stock. That's the PRIME DIRECTIVE. That way, one never ends-up stompin' aluminum cans at the dumpster in back of Starbucks. Very smart, Kool dude!! Heck, that's why your handle is 'Kool', dude!
This morning, however, some panic selling. It will come back, though. Some jitters behind approaching its 52-week high. Like I said, I ain't sellin' 'til it's up on the NASDAQ, at least. It will pass $1.00 shortly. No problem. FRET NOT!! Just remember what Jesus said to his Apostles & the gathered multitudes at his final Sermon On The Mount: "Guys, ya only go around ONCE in life, so you gots to grab all the Penny Stocks you can get!"
hey up/down.. actually made about 3 grand from 62 to 82...took out my original investment out so im free rolling....lets hope to see a lottery tix here
Hey, Posilock chap!! You NAILED it, dude! The NEXS folks are going to ROCK the OTC, NASDAQ, & NYSE like the "Chipolte" Mexican fastfood empire --- and you won't have to worry about contracting E. coli infections!!!!!
Helloooooo, Sylvia!! How'd ya get over here, at the NEXS board, young lady?! In any event, as I noted over on the XLIT forum, I did SELL all my XLIT. No big deal, but just got tired of waiting for olde James Schramm to reappear from 'sub-space'. If he can make his 'Electric Light Toilet Paper' fully RANDOM-DIGITAL, well, then XLIT will blast off to Andromeda Galaxy!
Hey, Koolyref dude. Charts; earnings reports (or lack thereof); the 'float'; etc., etc., have NOTHING to do with the present NEXS phenomenon. So then, WHAT is driving it UP? Answer: HOPE, and MONSTER potential. You will NEVER encounter a better 'penny stock' gamble than this one, my friend. Is it just a 'pump'?? Hey, dude, the boys over at "TradersChoice" are as excited about this one as Clark Gable HIMSELF was at the premier showing of, "Gone With The Wind" in 1939. (No, I wasn't there --- NOT that old!) But, can your money also be "gone with the wind" too, behind NEXS? Well, it is a GAMBLE. But, if you fancy, you can always SELL right now, if you like. And, more importantly than anything, you must understand that the OTC, NASDAQ, Pink Sheets, & even the NYSE are nothing more than GAMBLING CASINOS. But I ain't sellin' my NEXS chips, bucko! At least not until it's up on the NASDAQ. I'm ridin' this one to Jupiter, and beyond!
About a year ago, one of the WORST penny-stock-pickers --- "ExplosiveOTC" --- shot me a (weekend) email about a similar Medical Research penny stock selling for circa $0.79 per share. Well, I ignored that weekend pick. However, the following Monday, it EXPLODED over 7,000% --- YOU do the math --- and closed at circa $40.00 per share! Of course, such is extremely rare, but a lot LESS rare than winning the U.S. Mega Lottery. Hey dude, assuming your are a man with, 'a brain, a backbone, & two swinging nuts', just toss a couple grand at NEXS and see what happens. GOOD LUCK!!
up/downtrader, glad u are making money
http://www.nexusbiopharma.com/index.php/our-company/leadership
Leadership
WARREN C. LAU
President and Chief Executive Officer
Warren C. Lau is Nexus BioPharma Inc.'s President and Chief Executive Officer and Director, a position he has held since the formation of the company. Previously, Mr. Lau was a biotech entrepreneur and product development visionary many times over.
He also served as Founder, President and CEO, and Chief Financial Officer of MetaStat, Inc. (MTST-OTCBB) for six years.
In 2003, Mr. Lau founded PharmaFrontiers Corp. (now Opexa Therapeutics, Inc OPXA-NASDAQ). He also served as President, Chief Executive Officer, Treasurer and Board Member. Opexa has subsequently negotiated product development deals with Novartis AG and Merck Serono.
In 1996, Mr. Lau started Adventrx Pharmaceuticals, Inc., now Mast Therapeutics, Inc. (MSTX-NYSE MKT). He served as President and CEO and as a member of its Board of Directors from July 1996 through November 2001. During his time as President and CEO, the Company completed two acquisitions - with Immune Complex Corporation (1997) and Biokeys Pharmaceuticals, Inc.
From November 1997 to September 1998, Mr. Lau served as a director of Immune Complex Corporation and Synthetic Genetics, Inc., privately held biotechnology companies.
DR. JEFFREY PESSIN
Dr Pessin
PhD, Chair of Scientific & Clinical Advisory Board
Dr. Pessin is the Judy R. & Alfred A. Rosenberg Professorial Chair in Diabetes Research and Director of the Diabetes Research Center, Department of Medicine at the Albert Einstein College of Medicine.
He also serves as Professor in the Departments of Medicine (Endocrinology) and Molecular Pharmacology.
Dr. Pessin directs the Einstein-Mount Sinai Diabetes Research Center, one of only sixteen NIH-funded diabetes centers of its kind in the country.
He guides the research of more than 90 scientists investigating type 1 (formerly juvenile) and type 2 (formerly adult-onset) diabetes.
Dr. Pessin is associate editor of Diabetes, the peer-reviewed journal of the American Diabetes Association, and the former editor-in-chief of Endocrinology and the American Journal of Physiology - Endocrinology and Metabolism. He has received the Eli Lilly Outstanding Investigator Award of the American Diabetes Association and the Mary Jane Kugel Award of the Juvenile Diabetes Research Foundation International.
DR. DANIEL EINHORN
Dr einhorn
MD, Scientific & Clinical Advisory Board
Dan Einhorn, M.D. is medical director of the Scripps Whittier Diabetes Institute, clinical professor of medicine (voluntary) at UC San Diego, president of Diabetes and Endocrine Associates, and associate editor of the Journal of Diabetes.
Dr. Einhorn’s experience includes acting as a trustee and past-president of the American College of Endocrinology (ACE), a founding member and current regent of the ACE Foundation, and past-president of the American Association of Clinical Endocrinologists (AACE).
Dr. Einhorn received his BA at Yale (Summa cum Laude), his MD at Tufts (AOA) and his post-graduate training at Harvard.
He has been in leadership at AACE and ACE for over 20 years during which time he has participated in writing many national guidelines, including those for diabetes, pre-diabetes, inpatient diabetes management, and obesity.
Dr. Einhorn has been on the teaching faculty of every AACE/ACE annual meeting since 1994, chairing the meeting in 2009, and he continues to be a practicing physician.
He has devoted his practice exclusively to the care of adults with endocrine disorders, including diabetes, thyroid disease, osteoporosis, lipid disorders, polycystic ovarian syndrome, adrenal disease, parathyroid disease and diagnostic dilemmas that may have a hormonal origin.
I have been a share holder on other otc's in the same boat and no increase in pps TITXF ...nexs has 1 full time employee I tryed to get intouch with some one about investing and or wanting to b involved with trials for dibetis and left multiple messages..no response!
It may be the hiring if a woman who knows the fda approval process. Lots of pharmaceutical run to ridiculous values b/c they are working on a drug approval. If it fails or gets shut down b/c it's failing, them this thing will drop like a rock. Until then, over a year, it can run up big. This company is also working on a diabetes and alzheimer drug...not just diet.
I researched this company... looks like its the real deal. not a pump n dump by any means!! its legit. this is how otc stocks get uplisted to the big boards!
what is the the actual catalyst in the past 10 trading days for this to rise 40% It cant be the nexs last press release? can you back any accomplishments Nexs made for this price spike ? or just a pump and dump
"Pump-&-Dump"? It is, of course, a "TradersChoice" pick. However, this pick is much different. I exchange emails with TradersChoice people. And, they believe NEXS is the BEST penny stock gamble on this Planet. Great that you took some profits. But, I'll take my profits when NEXS is on the NASDAQ, or better. Bottom line, if a garden-variety Mexican fastfood joint --- i.e., "Chipolte" --- can hit an impossible $700.00+ stock price, then just wait to see what NEXS will do. And, you won't have to worry about contracting E.coli in the process!
so everyone knows Traders choice is stock tips! Mike Statler is back!
in at 62 out at 82.....Ill take profits and hope for a sell off..this looks like a pump and dump to me
"Up, up, and away! In my beautiful, my beautiful, NEXS skyrocketing penny stock!!" (Up over 18% just today, folks. Anybody listening? I'm getting LONELY posting every day to MYSELF on this board. I HATE when that happens!)
"Traders350" says, "YOU WOULD BE CRAZY" not to be watching NEXS very closely these days. (LINK) Are YOU watching it? Well, since I grabbed a nice chunk of it, I'm watching it! Go UP, and UP, and UP, and UP. Where are you going, American men & women, with you big, fat, butts!? How would you like a nice, little, pill to make you all skinny again?!
It is most definitely NOT time to "short this". Tim Sykes may "short this", at circa $5.00 to $6.00 --- on the NASDAQ. But not here, folks. (Sykes, by the way, wants $5,000 --- upfront --- to take his course on "shorting" penny stocks. I passed on that one.)
Everybody trashes "TradersChoice" as a 'pump-&-dump' routine. Myself, I already emailed to them my PRAISE for their NEXS pick. And, they replied with a thank-me for my compliments.
Bottom line, run your 'CHARTS' as you like, but WHO ELSE is picking penny stocks? I don't know how to do it. You don't know how to do it. So, I'll ride with "TradersChoice" picks anytime.
NEXUS BIOPHARMA is a legitimate GAMBLE. That's MY take, you guys have yours. Meanwhile, NEXS just keeps going up, and up, and up. Until you guys are tracking it on the NASDAQ.
They are saying, UP TO 1.6M
just look what they listed as received for XLIT :
THANKS for that 3-6-17 date behind TradersChoice, DaReal dude! VERY useful information! I put that date into my Google Calendar. And they are getting $1.6-mil. for their little ad campaign? Hey guys, I think maybe we should get into the penny stock promotion business!
Lol yeah they don't care when they are done with it.
That mail hit over night... Nasdaq uplist hehehe GL with that
Email not displaying correctly? View it in your browser.
Trade of the Year Logo (Image)
NEXS Seeks Nasdaq Listing in 2017
Valued members,
Our #1 trade of the year, Nexus Biopharma Inc. (NEXS) is off to an incredible start.
Since the beginning of September, NEXS has added over 78% to its market capitalization, creating significant value to shareholders and has turned into one of the fastest growing equities on the market today.
If you do not already hold NEXS in your portfolio, you are missing out on what may very well be one of the greatest trades of the decade—and that is not an exaggeration.
Remember, we know what a winner looks like. We have struck gold two years in a row, with COCP demonstrating over 500% returns in 2014/15 and XLIT providing over 900% to members in 2015/16. Those who paid attention to our alerts at the early stages walked away with considerable returns on the highs of both of those trades. View our track record here. http://www.otcmarkets.com/stock/COCP/chart
http://www.otcmarkets.com/stock/XLIT/chart guess they didnt check charts lately, LOL
If you have been struggling to make money in the markets recently, perhaps it is because you are not paying attention to the RIGHT companies. Do not hold on to losing situations. Cut your losses. Move capital into companies that are moving forward and are in strong up-trends.
With today's announcements, NEXS has—without a doubt—become the #1 equity to own moving into 2017.
If you have not yet already, read today's news from NEXS.
This is an incredible press release and an unbelievable early opportunity for our members to get involved with NEXS before the large funds begin to crowd-in and buy it up.
Some highlights of NEXS' accomplishments to date included:
Nexus (NEXS) Secured $2M of Institutional Funding
Nexus (NEXS) Appointed Jeffrey Pessin, Ph.D. to Advisory Board
Nexus (NEXS) Appointed Daniel Einhorn, M.D. to Advisory Board
Nexus (NEXS) Appointed Helen Stefanovic as Director of Regulatory Affairs
Nexus (NEXS) Filed International Patent to Extend Rights Internationally
Nexus (NEXS) Presented at the Royal Society of Chemistry Conference
Nexus Biopharma Inc. (NEXS) also clarified that its drug candidate will be orally administered. Most importantly, highlights of NEXS' plans going forward included:
Nexus (NEXS) Plans to Expand Into Multiple Indications Including:
- Treating Symptoms of Type II Diabetes
- Neurodegenerative Disease including Alzheimer's Disease
- Ageing, Another Blockbuster Opportunity
As if that wasn't enough, NEXS continued to surprise in its press release:
Nexus (NEXS) Seeks to Expand Its Pipeline With Synergistic Acquisitions
Nexus (NEXS) Meeting with the FDA by Q1 2017 for Pre-IND Regarding Phase 1
Nexus (NEXS) Will Commence Alzheimer's Studies in Q1 2017
Nexus (NEXS) Plans for Fast-Track Designation Meeting with FDA in Q3 2017
Nexus (NEXS) to Apply for Full Nasdaq Listing by Q3 2017
This was all contained in a single press release from the company. All we can say is... Wow!
NEXS is, hands down, the best company we have ever profiled.
Of all the companies out there, given today's news, NEXS most certainly deserves to be in the portfolio of a wise trader.
If you have any questions or do not understand why this is such a great trade, reply to this email. We are here to make sure you understand exactly how rare a situation like this truly is.
For those who may not be aware, NEXS is unlikely to remain sub-$4 for much longer. The minimum requirement to list on the Nasdaq is a $4 bid price. NEXS is planning to up-list by Q3 of 2017.
That pretty much all but guarantees NEXS will have to be $4+ by next September in order to gain its Nasdaq listing.
But that's a very conservative view.
With everything that NEXS has in store and the rate at which it is moving towards Phase-1 trials, once the IND filing goes through, NEXS is likely not going to be below $5 as large funds and firms rush to buy into the company that is developing the most promising weight-loss drug on the market today.
If you are not buying NEXS after reading this update, you have to seriously question your reasons for being in the markets at all.
Reward only comes to those who take the risk.
Those who risk it on NEXS are the only ones who will see the potential 1,000%+ returns here.
You have to make the leap and place your capital where you believe it will grow the greatest. What other companies do you have in your portfolio that will provide 500%+ returns in several months time? Do you have any that could go beyond and show 1,000%+? NEXS could.
Take time to study the facts here, this is one you want to dig into thoroughly and if you agree with our analysis, place your capital accordingly.
If you have not yet already, read the research report on NEXS below from industry professionals who have already given it a $9.73 target.
DOWNLOAD RESEARCH REPORT
They are still at it, til March 6th 2017 per their Disclaimer here:
http://www.tradeoftheyear.com/disclosures/
Yes they are still recommending this. I got a phone call from them a few hours ago about this stock.
TRADERS CHOICE IS NO LONGER PUMPING THIS, DID ANYONE GET THE NEW TICKER? May try to dump my shares thursday so i dont get a freeride R.
TRADERS CHOICE IS NO LONGER PUMPING THIS, DID ANYONE GET THE NEW TICKER? May try to dump my shares thursday so i dont get a freeride R.
A "scam"? Well, I just grabbed a nice chunk of NEXS today, and it even Closed up a little. This should not be compared to the "TradersChoice" XLIT debacle. I think there is real potential here. But it ain't gonna be an overnight sensation. "TradersChoice" is desperately trying to redeem itself after their XLIT trashing. I think NEXS is a step in the right direction.
Followers
|
9
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
300
|
Created
|
04/25/16
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |